 Connection
Kyle Molina to Drug Resistance, Multiple, Bacterial
This is a "connection" page, showing publications Kyle Molina has written about Drug Resistance, Multiple, Bacterial.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.258 |
|
|
|
-
Kunz Coyne AJ, Judd C, Lucas K, Al Musawa M, Van Helden S, Holger D, Althubyani A, Yost C, VanDorf S, Mynatt R, Kufel WD, Hayes J, Deri CR, Wrenn RH, Slaton CN, Morrisette T, Davis M, Cabanilla MG, Shald E, White BP, Sassine J, Truong J, Rosenberg J, Andrade J, Cerenzio J, Medvedeva N, Ha D, Eubank TA, Garey KW, Biagi M, Todd M, Kang-Birken SL, Rux C, Molina KC, Jankowski CA, Claeys KC, Venugopalan V, Veve MP, Orzol C, Eshaya M, Caniff KE, Bleick C, Rybak MJ. Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers. Antimicrob Agents Chemother. 2026 06 03; 70(6):e0026826.
Score: 0.058
-
Kunz Coyne AJ, Alosaimy S, Lucas K, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs ALV, Agee J, Perkins NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Zhao JJ, Witucki P, Rybak MJ. Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes. Microbiol Spectr. 2025 Oct 07; 13(10):e0056525.
Score: 0.055
-
Mueller SW, Molina KC, Blass B, Gibson C, Kohler AD, Krsak M, Wiktor AJ. Bone and Skin/Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug-Resistant Pseudomonas aeruginosa. J Burn Care Res. 2024 05 06; 45(3):808-810.
Score: 0.050
-
Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs AL, Agee J, Perkins NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2024 01 11; 12(1):e0235123.
Score: 0.049
-
Alosaimy S, Morrisette T, Lagnf AM, Rojas LM, King MA, Pullinger BM, Hobbs ALV, Perkins NB, Veve MP, Bouchard J, Gore T, Jones B, Truong J, Andrade J, Huang G, Cosimi R, Kang-Birken SL, Molina KC, Biagi M, Pierce M, Scipione MR, Zhao JJ, Davis SL, Rybak MJ. Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol Spectr. 2022 10 26; 10(5):e0047922.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|